Academic Editors: Anna Myriam Perrone and Michael H. Dahan
Background: Upregulating tumor cell targeting antigens and improving
the cytotoxicity of chimeric antigen receptor T cell (CAR-T) are expected to
facilitate better treatment efficacy for solid cancers represented by ovarian
cancer. Methods: Killer cell lectin-like receptor subfamily K member 1
ligands (NKG2DL) are the target antigens for ovarian cancer. NKG2D-CAR-T cells
were constructed for NKG2D ligand on the ovarian cancer cell surface. We used
flow cytometry to evaluate the expression of NKG2DL on SKOV3 (a human ovarian
cancer adenocarcinoma cell line). Innovatively, when combined with romidepsin to
treat ovarian cancer cell SKOV3, to evaluate the killing ability of the combined
strategy, we verified the cytotoxicity of CAR-T cells by lactate dehydrogenase
(LDH) release test and determined the secretion of cytokines by enzyme-linked
immuno sorbent assay (ELISA). Results: The results of flow cytometry
showed effective activation of the NKG2D-CAR-T cells, and romidepsin treatment
resulted in increased expression of NKG2DL on the surface of SKOV3. Cytotoxicity
test showed that romidepsin could enhance the killing ability of NKG2D-CAR-T
cells against ovarian cancer cells by regulating their NKG2DL expression (p